VFT
KLRA

Vanguard Fiduciary Trust’s Kailera Therapeutics KLRA Stock Holding History

Vanguard Fiduciary Trust’s Portfolio KLRA Stock Details KLRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.39M Buy
+290,128
New +$6.38M ﹤0.01% 2057

Other funds holding KLRA

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust's KLRA Position: Q2 2026 in Review

Vanguard Fiduciary Trust opened a new position in Kailera Therapeutics (KLRA) in Q2 2026: 290,128 shares worth $6.39M. The stake represents ﹤0.01% of the portfolio and ranks #2057 among its holdings.

47 funds tracked by Wall St. Rank hold KLRA as of Q2 2026.

  • Vanguard Fiduciary Trust held 290,128 shares of Kailera Therapeutics worth $6.39M as of Q2 2026.
  • Kailera Therapeutics was a new Vanguard Fiduciary Trust position in Q2 2026.
  • Kailera Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #2057 holding.
  • 47 funds tracked by Wall St. Rank held Kailera Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.